Skip to main content

Table 1 Patients‘demographic, clinical and histological characteristics. Patients were divided in two groups: vitamin D sufficient and insufficient using the baseline serum vitamin D level cut-off of 30 ng/mL (75 nmol/L)

From: Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer

  Vitamin D Sufficient
(n = 16)
Vitamin D Insufficient
(n = 66)
Total
(n = 82)
p-value
DEMOGRAPHIC DATA
Age (years), median [range] 55 [20–68] 52.5 [35–71] 53 [20–71] 0.6
Menopausal status, n (%)
 Pre-menopausal 6 (37.5) 29 (44.6) 35 (43.2) 0.6
 Post-menopausal 10 (62.5) 36 (55.4) 46 (56.8)
Missing 0   1   1  
CLINICAL DATA
ECOG score, n (%)
  0 16 (100) 59 (89.4) 75 (91.5) 0.3
  1 0 (0) 7 (10.6) 7 (8.5)
Weight (kg), median [range] 62 [48–88] 64.5 [40–95] 64 [40–95] 0.7
Height (cm), median [range] 164 [157–170] 161 [149–178] 162.5 [149–178] 0.3
BSA (m2), median [range] 1.71 [1.46–1.93] 1.71 [1.32–2.06] 1.71 [1.32–2.06] 0.9
BMI
  < 25 10 (62.5) 36 (54.5) 46 (56.1) 0.6
  ≥ 25 6 (37.5) 30 (45.5) 36 (43.9)
HISTOLOGICAL DATA
Histological grade, n (%)
  1 0 (0) 2 (3.0) 2 (2.5) 0.7
  2 8 (50) 39 (59.1) 47 (57.3)
  3 8 (50) 25 (37.9) 33 (40.2)
Perivascular invasion, n (%)
  No 10 (62.5) 48 (72.7) 58 (70.7) 0.5
  Yes 6 (37.5) 18 (27.3) 24 (29.3)
Estrogen receptor, n (%)
   < 10% 1 (6.2) 9 (13.6) 10 (12.2) 0.7
   ≥ 10% 15 (93.8) 57 (86.4) 72 (87.8)
Progesterone receptor, n (%)
   < 10% 3 (18.7) 18 (27.3) 21 (25.6) 0.7
   ≥ 10% 13 (81.3) 48 (72.7) 61 (74.4)
HER2 +, n (%)
  No 14 (87.5) 57 (87.7) 71 (87.7) 1
  Yes 2 (12.5) 8 (12.3) 10 (12.3)
  Missing 0   1   1  
Triple negative, n (%)
  No 15 (93.8) 60 (90.9) 75 (91.5) 1
  Yes 1 (6.2) 6 (9.1) 7 (8.5)
IJCC 2016 staging, n (%)
  I 9 (56.3) 21 (32.8) 30 (37.5) 0.5
  IIA 5 (31.2) 21 (32.8) 26 (32.5)
  IIB 2 (12.5) 15 (23.4) 17 (21.3)
  IIIA 0 (0.0) 6 (9.4) 6 (7.5)
  IIIC 0 (0.0) 1 (1.6) 1 (1.2)
  Missing 0   2   2  
  1. BSA Body Surface Area, BMI Body Mass Index, SBR Scarff-Bloom and Richardson, IJCC International Joint Committee on Cancer